Jon has been reporting on stock markets for over twenty-five years for audio text companies (remember them?!), newswires, and websites. He helped set up MarketEye News for ICV/Topic in the 1990’s before moving on to become a Markets reporter at AFX News. After over 10 years, which saw him rise to the dizzy heights of Markets Editor at AFX, the firm’s acquisition by Thomson Corp and subsequent takeover of Reuters, he moved on in 2012. Prior to Proactive Investors, he was News Editor for thisismoney.co.uk, the Mail Online’s financial website.
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
The analysts said "we have established a fair value for Summit which we believe more accurately reflects its fundamental value than the current share price of 24p”
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise
The Financial Times report, published online late on Friday, said the exact terms of the discussions had not been disclosed and added the talks may still not proceed to a deal
The AIM-listed clinical stage biotechnology said its company broker, Novum Securities issued 83,333,333 new ordinary shares at a price of 0.6p each with new and existing investors
Jamal Rushdy, Collagen Solutions’ CEO said "our decision to divest our shares does not preclude future potential opportunities to collaborate with Jellagen"
The group said the initial tranche will primarily serve to drive Glycotest's proprietary HCC Panel towards commercialisation in the US and to transfer the technology to Fosun
The Phase 3 programme comprises two global, randomised, double-blind, active-controlled clinical trials which will be run concurrently with each expected to enrol around 680 patients